-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Shi Bei
On December 3, the official website of CDE showed that the clinical application of Omeros's monoclonal antibody OMS721 (arsoplimab) injection targeting MASP-2 has been accepted by the State Food and Drug Administration.
The complement system plays a role in the inflammatory response and is activated due to tissue damage or microbial infection
Omeros has submitted a BLA application for OMS721 to the FDA for the treatment of thrombotic microangiopathy (HSCT-TMA) after hematopoietic stem cell transplantation.
In addition, OMS721 has also been developed for the treatment of IgA nephropathy.
The Phase III ARTEMIS-IGAN trial of OMS721 for the treatment of IgA nephropathy is ongoing